Skip to main content
CTOS 2024 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
BrochureWebsite

Cogent Biosciences

badg1
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies for genetically defined diseases. The Company’s lead program, bezuclastinib, is a potential best-in-class KIT mutant inhibitor in late-stage clinical trials in patients with Systemic Mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST). In addition, the Cogent Research Team is developing a pipeline of novel preclinical therapies targeting ErbB2, FGFR2, PI3Ka and KRAS.

Cogent Biosciences

PDF Files